EUVIMEDScopri EUVIMED
ValidierungsstudieKohortenstudieOpen access · CC BY-NC 4.0

Serum Villin‐1—A Novel Marker of Gut Barrier Damage in Acutely Decompensated Cirrhosis: A Cohort Study and Validation

David Tornai iD, Boglarka Balogh, Aniko Csillag, Andras Budai, Andras Kiss, Peter Antal-Szalmas, Gabor Mehes, Lukacs Barath, Tamas Tornai, Istvan Tornai, Zsuzsanna Vitalis, Nora Sipeki and 11 more

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.70481 ↗

At a glance

Validierungsstudie in Alimentary Pharmacology & Therapeutics, 2025. Written by David Tornai and 22 co-authors. Institution: Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary. Major MEDLINE topics: Liver Cirrhosis, Microfilament Proteins. Cited 2 times so far (Crossref); 42 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Ministry of Innovation and Technology of Hungary, Horizon 2020 Framework Programme, Ministry for Culture and Innovation of Hungary.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Gut barrier dysfunction contributes to acute decompensation (AD) of cirrhosis progression but, it is not acknowledged in severity or prognostic scores due to a lack of appropriate assessment tools.

Aim

We investigated serum villin‐1 (VIL1), an epithelial brush‐border associated actin‐binding protein, as a non‐invasive marker for gut injury and prognosis in AD cirrhosis.

Methods

Serum VIL1 was measured in 338 cirrhosis patients (discovery n = 130, validation n = 208, including acute‐on‐chronic liver failure [ACLF]) from MICROB‐PREDICT cohorts and 50 healthy controls (HC). Duodenal biopsies ( n = 49 patients, n = 11 HC) were assessed for tissue VIL1 via immunohistochemistry. Serum cytokine profiling linked serum VIL1 levels to systemic inflammation.

Results

Compared to HC, both serum and tissue VIL1 levels were lower in stable AD patients. However, serum VIL1 progressively increased with AD severity, peaking in ACLF. Serum VIL1 was associated with 90‐day mortality (AUROC: 0.721, p < 0.001; similar to MELD: 0.722, p < 0.001). A cut‐off > 12.79 ng/mL enhanced the prognostic accuracy provided by severe disease stage, defined as CLIF‐C AD score ≥ 50 or ACLF (low VIL1: 17.5% vs. high VIL1: 53.6% mortality). This threshold was associated with increased systemic inflammation, suggesting enhanced bacterial translocation. VIL1 was an independent predictor of 90‐day mortality (HR: 2.52, CI: 1.648–3.848, p < 0.001) in Cox regression. All findings were confirmed in the validation cohort.

Conclusion

Serum VIL1 is a non‐invasive indicator of gut barrier damage and short‐term mortality in AD cirrhosis. Incorporating VIL1 assessment into risk stratification methods improves prognostic accuracy by capturing an essential, yet previously overlooked component of disease progression.

Subjects

MeSH terms (MEDLINE)

Liver CirrhosisMicrofilament ProteinsHumansMaleFemaleBiomarkersMiddle AgedPrognosisCohort StudiesAgedAdultSeverity of Illness IndexDisease ProgressionAcute-On-Chronic Liver Failure

Author keywords

MICROB‐PREDICTacute‐on‐chronic liver failuregut barrier failureprognosisserological biomarkershort‐term mortality

Substances

BiomarkersMicrofilament Proteinsvillin

Authors and institutions

  • Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Kalman Laki Doctoral School of Biomedical and Clinical Sciences, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Department of Pathology, Forensic and Insurance Medicine, Faculty of Medicine, Semmelweis University, Budapest, Hungary.
  • Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Department of Pathology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Institute of Pancreatic Diseases, Semmelweis University, Budapest, Hungary.

ORCID profiles: David Tornai, Richard Moreau, Jonel Trebicka, Maria Papp

Funding

  • Ministry of Innovation and Technology of Hungary
  • Horizon 2020 Framework Programme
  • Ministry for Culture and Innovation of Hungary
  • Magyar Tudományos Akadémia

Cite

APA

Tornai, D., Balogh, B., Csillag, A., Budai, A., Kiss, A., Antal-Szalmas, P., Mehes, G., Barath, L., Tornai, T., Tornai, I., Vitalis, Z., Sipeki, N., Dinya, T., Enyedi, A., Rosenberger, F. A., Laleman, W., Coenraad, M. J., Aguilar, F., Claria, J., …, & MICROB‐PREDICT and PREDICT study group of the EASL‐CLIF consortium (2025). Serum Villin‐1—A Novel Marker of Gut Barrier Damage in Acutely Decompensated Cirrhosis: A Cohort Study and Validation. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70481

Vancouver

Tornai D, Balogh B, Csillag A, Budai A, Kiss A, Antal-Szalmas P, et al. Serum Villin‐1—A Novel Marker of Gut Barrier Damage in Acutely Decompensated Cirrhosis: A Cohort Study and Validation. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70481

BibTeX
@article{Tornai2025,
  author = {Tornai, David and Balogh, Boglarka and Csillag, Aniko and Budai, Andras and Kiss, Andras and Antal-Szalmas, Peter and Mehes, Gabor and Barath, Lukacs and Tornai, Tamas and Tornai, Istvan and Vitalis, Zsuzsanna and Sipeki, Nora and Dinya, Tamas and Enyedi, Attila and Rosenberger, Florian A and Laleman, Wim and Coenraad, Minneke J and Aguilar, Ferran and Claria, Joan and Moreau, Richard and Trebicka, Jonel and Papp, Maria and MICROB‐PREDICT and PREDICT study group of the EASL‐CLIF consortium, MICROB‐PREDICT and PREDICT study group of the EASL‐CLIF consortium},
  title = {Serum Villin‐1—A Novel Marker of Gut Barrier Damage in Acutely Decompensated Cirrhosis: A Cohort Study and Validation},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.70481}
}
Start for free →